News about Clinical Trials

Acumen Announces First Patient Dosed in ALTITUDE-AD

Acumen Pharmaceuticals, Inc. has announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.

Clinical Trials | 08/05/2024 | By Aishwarya |  490

Pepper Bio to Gain Exclusive Rights for Clinical Development of Lerociclib

G1 Therapeutics, Inc. has inked a global licensing agreement (excluding the Asia-Pacific region) with Pepper Bio for lerociclib for all indications except for certain radioprotectant uses.

Clinical Trials | 03/05/2024 | By Aishwarya |  507

Parexel Join Hands with Palantir to Boost Clinical Data Delivery for Patients

Parexel has forged a multi-year strategic partnership with Palantir Technologies Inc. to leverage AI to help enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharmaceutical customers.

Clinical Trials | 29/04/2024 | By Aishwarya |  1235

Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

Clinical Trials | 04/08/2023 | By Sudeep Soparkar |  592

SMC unveils Cambridge Pharma

The new business will offer pharmaceutical development services, including sterile fill-finish

Clinical Trials | 07/09/2022 | By Sudeep Soparkar |  726

3D model created for rare neuromuscular disorder

Scientists have created a bioengineered 3-D model that mimics the biology of two rare diseases. The researchers used the 'tissue chip' model to show how a drug could potentially treat the diseases, providing data for a drug company's FDA submission for authorization for clinical testing.

Clinical Trials | 04/05/2022 | By Sudeep Soparkar |  776

New patent grant to OSE Immunotherapeutics by EPO

OSE Immunotherapeutics receives European patent covering novel myeloid immune checkpoint target, CLEC-1 for cancer treatment

Clinical Trials | 03/05/2022 | By Sudeep Soparkar |  902

EMA reviews gene therapy for Haemophilia B

EMA (European Medicines Agency) has started reviewing the CSL Behring's MAA for gene therapy etranacogene dezaparvovec (EtranaDez), for the patients getting treatment for Haemophila B.

Clinical Trials | 28/04/2022 | By Sudeep Soparkar |  899

ALS drug by Biogen and Ionis Pharmaceuticals fails in trials

Biogen and Ionis Pharmaceuticals were hoping to be the first to find a cure for ALS. That dream has now fizzled out with the companies calling it quits after receiving disappointing results from a phase 1 clinical trial.

Clinical Trials | 27/04/2022 | By Sudeep Soparkar |  703

Anti-Tigit drug of Roche fails stage study

Roche's Genentech had disappointing news to share this week regarding its lung cancer hopeful.

Clinical Trials | 26/04/2022 | By Sudeep Soparkar |  807